Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Conditions: Clostridium Tetanus Interventions: Drug: Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation; Drug: Tetanus human immunoglobulin (HTIG); Drug: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo; Biological: Adsorbed tetanus vaccine (TT) Sponsors: Changchun BCHT Biotechnology Co.; The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine; Anning City First People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
Conditions: Healthy Volunteers Interventions: Biological: Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed); Biological: Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed); Biological: Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Conditions: Vaccine Immunity in CAR-T Cell Therapy Recipients Interventions: Biological: Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles Sponsors: Insel Gruppe AG, University Hospital Bern Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.
Conditions: Pain; Pediatrics; Vaccination; Virtual Reality Interventions: Device: Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet; Behavioral: Traditional Distractors; Biological: Triple Viral + Varicella Vaccine at 3 years of age; Biological: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age. Sponsors: Fundacio d ' Investigacio en Atencio Primaria Jordi Gol i Gurina Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults
Conditions: Tetanus Interventions: Biological: GR2001; Biological: Placebo; Biological: HTIG; Biological: Tetanus Toxoid Sponsors: Genrix (Shanghai) Biopharmaceutical Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy
Conditions: Pertussis (Whooping Cough) Interventions: Other: Not applicable / database analysis Sponsors: Sanofi Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam
Conditions: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine Sponsors: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Conditions: Diphtheria; Tetanus; Pertussis Interventions: Biological: DTacP (one-dose booster); Biological: DTacP (three-dose primary vaccination); Biological: DT (one-dose booster); Biological: DTaP (one-dose booster); Biological: PENTAXIM (one-dose booster); Biological: DTaP (three-dose primary vaccination); Biological: PENTAXIM (three-dose primary vaccination) Sponsors: Institute of Medical Biology, Chinese Academy of Medical Sciences; Sichuan Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials
A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study
Conditions: Meningococcal Immunization Interventions: Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).; Biological: Meningococcal Group C-CRM197 Conjugate Vaccine Sponsors: Sanofi Pasteur, a Sanofi Company Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy
Conditions: Non-birthing Partner Vaccination in Pregnancy; Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination; Vaccine Exposure During Pregnancy Interventions: Behavioral: Education; Biological: Vaccine administration Sponsors: Women and Infants Hospital of Rhode Island Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas
Conditions: Granuloma; Aluminum Allergy Interventions: Diagnostic Test: Aluminum; Diagnostic Test: Tetanus toxoid Sponsors: National Allergy Research Center, Denmark Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
Conditions: Tetanus Interventions: Biological: TTVA; Biological: TT Sponsors: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Randomized, Blinded, Positive-controlled Clinical Trial Evaluating the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
Conditions: Tetanus Interventions: Biological: TTVA; Biological: TT Sponsors: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
Conditions: Tetanus Interventions: Biological: TTVA; Biological: TT Sponsors: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Conditions: Follicular Lymphoma Interventions: Diagnostic Test: Cellular immunity vs SARS-CoV-2; Diagnostic Test: Humoral immunity vs SARS-CoV-2; Diagnostic Test: Cellular immunity vs Varicella Zoster Virus; Diagnostic Test: Humoral immunity vs Varicella Zoster Virus; Diagnostic Test: Diphtheria toxin-binding IgG; Diagnostic Test: Tetanus toxoid-binding IgG; Diagnostic Test: T-cell populations and markers characterization Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
